<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=191315034553936&amp;ev=PageView&amp;noscript=1">
Our client Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO

Read More

 

Bispecific T cell Engager (BiTE®) technology is designed to bind polyclonal cytotoxic T cells and targeted malignant cells1,2,8

Read More

Find Out More